78146 research outputs found
Sort by
Ship sensors data collection and analysis for condition monitoring of ship structures and machinery systems
No full textWith the advancements in technology, sensors and predictive maintenance, the concept of smart ships aims in using data to enhance ship performance. The INCASS project aims in integrating robotic platforms, structural and machinery reliability tools in order to enhance ship inspection, maintenance, safety and performance. In order to achieve this, sensors are installed onboard three case studies, for monitoring hull structural characteristics and machinery parameter measurements are also monitored and data are collected in order to inspect and examine machinery systems and parameters behaviour through condition monitoring. Moreover, INCASS also addresses and identifies the methods for transforming the real time monitoring data (raw data), collected from the onboard measurement campaign using permanent sensors or portable equipment or a combination of both, into meaningful, useful data and information that will be utilised in developed structural and machinery reliability analysis and assessment tools. Furthermore, the developed tools using the information from the onboard data collection activity will be capable of calculating and assessing the performance and reliability of the ship, which will provide input into a decision support system capable of addressing emergency decision making and assisting in the overall decision making process for repair, maintenance and optimised ship operations
The Financing of Diverse Enterprises : Evidence from the SME Finance Monitor
No full textThis paper contributes to our understanding of the finance issues currently facing diverse SMEs by presenting a new analysis of the SME Finance Monitor. While prior studies have contributed substantial evidence regarding the effects of either gender or ethnicity on finance outcomes, these analyses have typically focused on either women-owned or ethnic minority owned enterprises. This study considers the experiences and outcomes of both women-owned and ethnic minority-owned enterprises, including the interaction effects of ethnicity and gender
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma
No full textBACKGROUND: Poorly controlled asthma and preventable exacerbations place a significant strain on healthcare, often requiring additional medications, hospital stays or treatment in the emergency department.Long-acting beta2-agonists (LABA) are the preferred add-on treatment for adults with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS), but have important safety concerns in asthma. Long-acting muscarinic antagonists (LAMA) have confirmed efficacy in chronic obstructive pulmonary disease and are now being considered as an alternative add-on therapy for people with uncontrolled asthma. OBJECTIVES: To assess the efficacy and safety of adding a LAMA to ICS compared with adding a LABA for adults whose asthma is not well controlled on ICS alone. SEARCH METHODS: We searched the Cochrane Airways Group's Specialised Register (CAGR) from inception to April 2015, and imposed no restriction on language of publication. We searched additional resources to pick up unpublished studies, including ClinicalTrials.gov, World Health Organization trials portal, reference lists of primary studies and existing reviews, and manufacturers' trial registries. The most recent search was conducted in April 2015. SELECTION CRITERIA: We searched for parallel and cross-over RCTs in which adults whose asthma was not well controlled with ICS alone were randomised to receive LAMA add-on or LABA add-on for at least 12 weeks. DATA COLLECTION AND ANALYSIS: Two review authors independently screened the electronic and additional searches and extracted data from study reports. We used Covidence for duplicate screening, extraction of study characteristics and numerical data, and risk of bias ratings.The pre-specified primary outcomes were exacerbations requiring oral corticosteroids (OCS), quality of life and serious adverse events. MAIN RESULTS: We included eight studies meeting the inclusion criteria, but four double-blind, double-dummy studies of around 2000 people dominated the analyses. These four trials were between 14 and 24 weeks long, all comparing tiotropium (usually Respimat) with salmeterol on top of medium doses of ICS.Studies reporting exacerbations requiring OCS showed no difference between the two add-ons, but our confidence in the effect was low due to inconsistency between studies and because the confidence intervals (CI) included significant benefit of either treatment (odds ratio (OR) 1.05, 95% CI 0.50 to 2.18; 1753 participants; 3 studies); three more people per 1000 might have an exacerbation on LAMA, but the CIs ranged from 29 fewer to 61 more. Imprecision was also an issue for serious adverse events and exacerbations requiring hospital admission, rated low (serious adverse events) and very low quality (exacerbations requiring hospital admission), because there were so few events in the analyses.People taking LAMA scored slightly worse on two scales measuring quality of life (Asthma Quality of Life Questionnaire; AQLQ) and asthma control (Asthma Control Questionnaire; ACQ); the evidence was rated high quality but the effects were small and unlikely to be clinically significant (AQLQ: mean difference (MD) -0.12, 95% CI -0.18 to -0.05; 1745 participants; 1745; 4 studies; ACQ: MD 0.06, 95% CI 0.00 to 0.13; 1483 participants; 3 studies).There was some evidence to support small benefits of LAMA over LABA on lung function, including on our pre-specified preferred measure trough forced expiratory volume in one second (FEV1) (MD 0.05 L, 95% CI 0.01 to 0.09; 1745 participants, 4 studies). However, the effects on other measures varied, and it is not clear whether the magnitude of the differences were clinically significant.More people had adverse events on LAMA but the difference with LABA was not statistically significant. AUTHORS' CONCLUSIONS: Direct evidence of LAMA versus LABA as add-on therapy is currently limited to studies of less than six months comparing tiotropium (Respimat) to salmeterol, and we do not know how they compare in terms of exacerbations and serious adverse events. There was moderate quality evidence that LAMAs show small benefits over LABA on some measures of lung function, and high quality evidence that LABAs are slightly better for quality of life, but the differences were all small. Given the much larger evidence base for LABA versus placebo for people whose asthma is not well controlled on ICS, the current evidence is not strong enough to say that LAMA can be substituted for LABA as add-on therapy.The results of this review, alongside pending results from related reviews assessing the use of LAMA in other clinical scenarios, will help to define the role of these drugs in asthma and it is important that they be updated as results from ongoing and planned trials emerge
Resolvent estimates in homogenisation of periodic problems of fractional elasticity
No full textWe provide operator-norm convergence estimates for solutions to a time-dependent equation of fractional elasticity in one spatial dimension, with rapidly oscillating coefficients that represent the material properties of a viscoelastic composite medium. Assuming periodicity in the coefficients, we prove operator-norm convergence estimates for an operator fibre decomposition obtained by applying to the original fractional elasticity problem the Fourier--Laplace transform in time and Gelfand transform in space. We obtain estimates on each fibre that are uniform in the quasimomentum of the decomposition and in the period of oscillations of the coefficients as well as quadratic with respect to the spectral variable. On the basis of these uniform estimates we derive operator-norm-type convergence estimates for the original fractional elasticity problem, for a class of sufficiently smooth densities of applied forces
Single atom imaging with an sCMOS camera
No full textSingle atom imaging requires discrimination of weak photon count events above background and has typically been performed using either EMCCD cameras, photomultiplier tubes or single photon counting modules. sCMOS provides a cost effective and highly scalable alternative to other single atom imaging technologies, offering fast readout and larger sensor dimensions. We demonstrate the first single atom resolved imaging of two site-addressable single atom traps separated by 10 μm using an sCMOS camera, offering a competitive signal-to-noise ratio at intermediate count rates to allow high fidelity readout discrimination (error < 10−6) and sub-μm spatial resolution for applications in quantum technologies
Access Repository Dashboard
Do you manage University of Strathclyde Institutional Repository? Access insider analytics, issue reports and manage access to outputs from your repository in the CORE Repository Dashboard!